Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Marathon Pharma

    - PMLiVE

    Novo Nordisk agrees to lower certain drug prices in the US

    The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

    - PMLiVE

    Lilly announces agreement with US government to lower patient costs

    The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

    Genesis Research Group A&P image

    Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.

    In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...

    Genesis Research Group

    - PMLiVE

    Communicating value to US Payers: Insights for Pharma and Medtech

    What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging...

    Petauri Evidence

    - PMLiVE

    Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

    The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

    - PMLiVE

    MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy

    The severe neuromuscular disease affects approximately 2,500 people in the UK

    - PMLiVE

    NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

    Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

    - PMLiVE

    What is willingness to pay? – Comparing price testing methodologies

    Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...

    Petauri Evidence

    - PMLiVE

    FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

    The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

    - PMLiVE

    Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

    Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

    Inizio

    - PMLiVE

    Ten participating drugmakers invited for further US Medicare drug price negotiations

    ASPE revealed that the IRA is expected to save around 857,000 US women $1,000 or more in 2025

    - PMLiVE

    FDA approves Italfarmaco’s Duvyzat as first nonsteroidal Duchenne muscular dystrophy drug

    The neuromuscular genetic disease is estimated to affect one in every 3,500 to 6,000 male births worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links